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Background: Several health authorities have recently revised the indication of inﬂ  iximab 
(IFX) to include the treatment of early rheumatoid arthritis (RA). The aim of this systematic 
review of the literature was to appraise the efﬁ  cacy, safety, and cost-effectiveness of early 
therapy with IFX.
Methods: We identiﬁ  ed published clinical trials from 1966 to May 2006. We included ran-
domized clinical trials (RCTs) in RA with disease duration of less than 3 years comparing the 
treatment of methotrexate-IFX (MTX-IFX) with methotrexate-placebo (MTX-placebo).
Results: A total of 8 studies met inclusion criteria. Three studies reported redundant data 
regarding the vdH Sharp Score. Out of the 5 remaining studies, 4 analyzed structural joint 
destruction (vdH Sharp Score) and demonstrated a signiﬁ  cant reduction in radiographic damage 
progression in favor of the combination of MTX-IFX compared with MTX-placebo (–4.1 vdH 
Sharp Score units (95% CI: 3.5; 4.6). Three studies also displayed a beneﬁ  t of MTX-IFX on 
functional outcomes of RA (HAQ score) and disease activity measures (DAS, ACR response 
criteria), although less markedly.
Conclusions: Although data might be skewed because of only 2 existing large studies with 
concordant data, results from RCTs demonstrate improved efﬁ  cacy of the combination MTX-
IFX compared with MTX-placebo in early RA. However, many early RA patients probably 
do not require the addition of IFX to achieve a satisfying clinical and radiological course. So 
far, no evidence has established the superiority of MTX-IFX over MTX-prednisone or other 
combinations of traditional disease-modifying anti-rheumatic agents.
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Introduction
Rheumatoid arthritis (RA) is a chronic inﬂ  ammatory disease associated with progres-
sive irreversible joint damage and major permanent disability. Rheumatoid arthritis 
is the most common systemic rheumatic disease, affecting approximately 1% of the 
adult population, with a maximum incidence between ages 35 to 55 (Silman 2001). 
Its overall economic consequences for society are comparable with that of coronary 
artery disease (Callahan 1998) and its impact on individuals is considerable, as the 
disease leads to progressive restricted joint mobility, pain, and functional disability. 
The disease’s relatively early onset in life means that it affects the working-age 
population, resulting in a work disability rate 10 times higher than an age- and sex-
matched population with enormous indirect costs due to lost productivity (Felts et al 
1989). Two years after diagnosis, 20% of RA patients stop their professional activity 
and more than 50% will be work-disabled after 10 years of disease (Young et al 2002). 
Rheumatoid arthritis also increases mortality, with survival similar to that of patients 
with lymphoma or severe ischemic heart disease (Pincus 1998).
The treatment of RA is still unsatisfactory, but a number of new and more powerful 
disease-modifying antirheumatic drugs (DMARDs) have become available, such Therapeutics and Clinical Risk Management 2007:3(5) 906
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as anti-TNF agents, B-cell depleting agents, or selective 
costimulation inhibitors. Until 15 years ago, the recom-
mended therapeutic strategy was to start with non-steroidal 
anti-inﬂ  ammatory drugs (NSAIDs) or low-dose glucocor-
ticoids, and only if these were insufﬁ  cient to control the 
disease, more potent antirheumatic therapies were progres-
sively introduced (pyramid approach). In the past 15 years, 
treatment goals have evolved from “symptom-control” to a 
broader concept of “disease control” (Edmonds et al 1993). 
Controlling joint destruction has become the major objec-
tive for treating RA (ACR 2002), because radiographic 
joint damage correlates strongly with long-term functional 
decline in RA patients (Scott et al 2003). Key agents in this 
strategy are DMARDs, which have been shown to control 
progressive structural joint damage. These therapies improve 
morbidity and mortality in RA and increase quality-adjusted 
life expectancy to an extent similar to the effects of adjuvant 
chemotherapy for metastatic breast cancer or beta-blocker 
therapy for patients at moderate risk of recurrent myocardial 
infarction (Barbieri et al 2005).
Recent changes in RA treatment paradigms have 
resulted in a more aggressive therapeutic approach (Wilske 
et al 1989), with initiation of antirheumatic drugs before 
signiﬁ  cant structural joint occurs. The rationale for a prompt 
initiation of DMARDs in early RA is based on the “window 
of opportunity” paradigm. The early stages of the disease 
appears to be a critical period for the treatment of RA; treat-
ments early are more effective than later in the course of the 
disease and might permanently modify the disease to a milder 
course (Combe et al 2006; Finckh et al 2006). Nevertheless, 
health authorities, in most countries still limit the use of the 
more expensive biologic agents to patients who have failed 
one or several traditional DMARDs, which effectively 
eliminates these agents from the management of early RA. 
Recently, however, health authorities in several countries 
have revised the indication of inﬂ  iximab (IFX) to include 
the treatment of early RA (Schering-Plough 2006).
To appraise the efﬁ  cacy, safety, and cost-effectiveness of 
early therapy with IFX, we conducted a systematic review 
of the literature and performed a meta-analysis of the RA 




We identiﬁ  ed all studies in any language on therapy with 
IFX in early RA by a systematic search of the literature and 
electronic databases, including MEDLINE (1966–May 2006), 
EMBASE (1974–May 2006), and the Cochrane controlled 
trial registry. We also reviewed abstracts from the American 
College of Rheumatology (ACR) and the European League 
Against Rheumatism scientiﬁ  c meetings from 2004 through 
2005 and contacted companies producing IFX (Essex and 
Centocor) for unpublished data. Search terms were: “Rheu-
matoid arthritis” OR “arthritis”, AND “early”, AND “random-
ized controlled trial”. We searched for additional studies by 
scrutinizing bibliographies of articles.
Study inclusion criteria were:
•  Subjects diagnosed with RA using ACR criteria (Arnett 
et al 1988)
•  Disease duration less than 3 years (“early RA”).
•  Randomized controlled trials (RCT)
Exclusion criteria:
• Duplicate  data
Statistical analysis
A meta-analysis of the radiographic data was performed 
using the van der Heijde-Sharp (vdH-S) score, reported in 
most studies. We computed the mean difference in change 
scores between the two treatment groups and computed the 
standard deviation of the change score by assuming unpaired 
data (Deeks et al 2004). All analyses were performed with 
STATA version 9.2 meta-analysis routines. We used ﬁ  xed 
effects models with an α-error of 0.05.
Results
Seventeen original studies were identiﬁ  ed using our biblio-
graphic search criteria, of which 8 abstracts corresponded to 
our inclusion criteria. The 9 remaining dealt either with other 
rheumatological conditions (ankylosing spondylitis, psoriasic 
arthritis) or with fundamental research. For the meta-analysis 
of vdH-S score, 3 of the 7 studies reporting joint destruction 
were excluded (duplicate data), 2 of which used the ASPIRE 
data (Smolen et al 2006a, 2006b) and the third used the same 
patients as in Taylor et al (2004).
Disease activity
In RA, disease activity and response to therapy are generally 
assessed with composite scores, which incorporate clinical 
assessment parameters, the acute phase reactants (erythrocyte 
sedimentation rate [ESR] or C-reactive protein [CRP]) and 
patient data. The ACR response criteria include a tender and 
swollen joint count, a patient’s and the physician’s global 
assessment, acute phase reactants, a pain scale, and a functional 
questionnaire. An ACR response of 20, 50, and 70 reﬂ  ects an 
improvement in several of these measures of at least 20%, Therapeutics and Clinical Risk Management 2007:3(5) 907
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50%, and 70% respectively (Felson et al 1995). The disease 
activity score (DAS 28) is a composite score including the 
swollen joint count, the tender joint count, the ESR, and the 
patient’s global assessment. The DAS ranges from 0 to 10, 
0 representing no disease activity and 10 a maximum. Both 
composite measures correlate reasonably well with short-term 
structural damage and employability (Graudal et al 2000; 
Jansen et al 2001; Combe et al 2006). The largest double 
blind RCT, the ASPIRE trial (St Clair et al 2004), included 
1049 patients, and compared the effect of methotrexate-IFX 
(MTX-IFX) with MTX-placebo on clinical, radiological, and 
functional scores at 1 year. Patients were randomized in 1 of 3 
treatment strategies: MTX-IFX 3 mg/kg, MTX-IFX 6 mg/kg, 
or MTX-placebo. A statistically signiﬁ  cant difference in the 
ACR 20, 50, and 70 scores was demonstrated at 1 year in 
favor of the MTX-IFX regimen, but statistically signiﬁ  cant 
advantages in the DAS 28 score were observed only in the 
highest IFX dosage group. At 1 year, depending on the IFX 
doses, 62%–66% of patients reached an ACR 20 response in 
the MTX-IFX combination group compared with 53% in the 
MTX-placebo group; 45%–50% reached an ACR 50 in the 
MTX-IFX group compared with 32% in the MTX-placebo 
group; and 32%–37% reached an ACR 70 in the MTX-IFX 
group compared with 21% in the MTX-placebo group. The 
DAS 28 score improved by 43%–48% in the combina-
tion therapy group and by 30% in the MTX-placebo group 
(St Clair et al 2004). Similar trends were found in a smaller 
trial, although the difference between groups did not neces-
sarily reach signiﬁ  cance (Quinn et al 2005). Interestingly, the 
ASPIRE trial revealed that ESR and CRP levels correlated 
with progressive joint damage only in the MTX-placebo group, 
suggesting that patients treated with MTX-IFX achieved 
radiographic beneﬁ  t regardless of the effects on the clinical 
and biological parameters (Smolen et al 2006).
Overall, the results of the different RCTs comparing 
MTX-IFX with MTX alone indicate that improvements on 
measures of disease activity are relatively modest.
Disease progression
The true measure of disease progression in RA is generally 
thought to be long-term outcomes such as severe disability 
or surgical joint replacement. Since these outcomes occur 
late in the disease, measurable proxy outcomes have been 
developed, such as radiographic joint damage or functional 
disability indices. Radiographic joint damage represents the 
cumulative natural history of the disease in the individual 
patient. Many studies have shown convincingly that the 
level of radiographic damage of the joints is associated 
with long-term loss of function and long-term disability. 
Radiographic measures of structural joint damage are cur-
rently considered the “gold standard” for treatment efﬁ  cacy 
studies (van der Heijde 2000). Thus, prevention or control 
of progressive joint damage has become a crucial goal for 
clinicians managing RA (ACR 2002) and has been recog-
nized as a primary goal by the US Food and Drug Adminis-
tration (Boers 1999). The most commonly used instrument 
to assess radiographic joint damage is a semi-quantitative 
scoring system known as the vdH-S score (van der Heijde 
2000). The score ranges from 0 to 448 and includes an ero-
sion score and a joint-space-narrowing score based on hand 
and feet plain X-rays. Because of the limited sensitivity to 
change of conventional X-rays, ultrasound (US) and mag-
netic resonance imaging (MRI) have also started to be used 
to assess structural joint damage progression but the imaging 
techniques are not yet validated for clinical trials.
Functional disability in RA is generally assessed with the 
Stanford Health Assessment Questionnaire (HAQ), which 
is a 20 item self-report questionnaire ranging from 0 to 3. 
The HAQ tends to increase slowly over time in patients with 
RA (average of 0.03 units per year and has been shown to 
predict work disability, joint replacement, medical costs, 
and mortality (Michaud et al 2005; Wolfe et al 1998) in RA. 
Radiographic damage and HAQ scores correlate rather well 
in advanced disease (Welsing et al 2001).
Radiographic joint damage was a primary outcome in 4 
out of 8 studies (the 3 redundant studies having been excluded 
and 1 study not reporting conventional radiologic data). 
All the studies showed signiﬁ  cantly less progression on the 
vdH-S score in the MTX-IFX group. The pooled results from 
these 4 studies including a total of 1647 patients showed a 
reduction in radiographic progression of 4.1 vdH-S score 
units (95% CI: 3.5; 4.6) per year in the MTX-IFX com-
pared with the MTX-placebo groups (Breedveld et al 2004; 
St Clair et al 2004; Taylor et al 2004; Goekoop-Ruiterman 
et al 2005; Quinn et al 2005). The protective effect of IFX-
MTX on radiographic damage progression was not signiﬁ  -
cantly better with higher dosages of IFX (p = 0.82).
Three small studies examined the progression of structural 
damage with other means than conventional radiography 
(MRI follow up and joint US with power doppler). Syno-
vitis, bone edema, and erosions were scored on MRIs of 
the 2nd to the 5th metacarpophalangial joints and total 
synovial thickness and vascularity assessments were scored 
by US Power Doppler imagery. These studies conﬁ  rmed 
the superiority of the MTX- IFX to MTX alone in early RA 
(Taylor et al 2004; Quinn et al 2005; Taylor et al 2006).Therapeutics and Clinical Risk Management 2007:3(5) 908
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Three out of 8 studies used the functional disability 
(HAQ) score as an endpoint. Just as for radiographic damage 
progression, all 3 studies showed an advantage in the HAQ 
improvement for the MTX-IFX combination compared with 
the control group. Patients on MTX-placebo improved their 
HAQ scores on average by 18%–50%, whereas patients 
on MTX-IFX combination improved their HAQ scores 
by 58%–80% after 1 year of follow up, depending on the 
studies (Breedveld et al 2004; St Clair et al 2004; Goekoop-
Ruiterman et al 2005; Quinn et al 2005). One analysis 
(Smolen et al 2006) focused on the effect on employability 
in early RA and found a greater ability of patients treated 
with the IFX-MTX to keep their job, but failed to demon-
strate a difference of employment rates between patients 
treated with or without IFX. One smaller study showed 
an effect on function which persisted even after IFX was 
stopped. The effect on functional disability in favor of the 
MTX-IFX was maintained 1 year after interruption of IFX 
(Quinn et al 2005).
Safety
Many questions concerning safety of anti-TNF agents have 
been raised, particularly concerning an increased risk of 
infections and tumors. Three studies using IFX in early RA 
reported treatment side effects. The BEST study (Goekoop-
Ruiterman et al 2005), a multi-center RCT including 508 
patients, compared 4 different treatment strategies and 
reported the side effects in each group. The ﬁ  rst group was 
treated with sequential monotherapy of traditional DMARDs; 
the second group with a step-up combination therapy of tra-
ditional DMARDs; the third group with prednisone (quickly 
tapered to 7.5 mg/day), MTX, and sulfasalazine; the fourth 
group with MTX-IFX. The BEST study concluded that there 
was no statistical signiﬁ  cant difference in the frequency of 
side effects or treatment withdrawal between the 4 treat-
ment groups. Nine out 121 patients were found to have 
latent tuberculosis before treatment initiation of MTX- IFX 
and took isoniazide before starting IFX, and none of them 
developed active tuberculosis. The largest study in early RA 
including 1049 patients (ASPIRE) reported signiﬁ  cantly 
more pneumonias in patients treated with MTX-IFX than 
with MTX alone (2% in the MTX- IFX group vs 0% in the 
placebo MTX group). The frequency of other infections 
(upper respiratory infections, sinusitis, pharyngitis) were 
similar between the MTX-IFX and MTX-placebo groups. 
In the same study, 4 patients, all in the MTX-IFX group, 
developed tuberculosis. Two of them had a negative PPD 
skin test before the start of IFX.
Four solid tumors in the MTX-IFX high-dose group 
(6 mg/kg), but none in the MTX-IFX low-dose group (3 mg/kg) 
or in the placebo group, were reported in the ASPIRE trial 
(Breedveld et al 2004; St Clair et al 2004). The BEST study 
reported a bladder carcinoma in the step up group and one 
breast cancer and one lymphoma in the prednisone, MTX, 
and sulfasalazine group (Goekoop-Ruiterman et al 2005), 
but no malignancy was observed in the MTX-IFX group. 
Because of limited sample sizes and duration of follow up in 
RCTs, deﬁ  nite conclusions cannot be drawn about the poten-
tial carcinogenic risk of IFX in early RA. Side effects such as 
heart failure have not been reported in these patients.
A meta-analysis of infectious and carcinogenic complica-
tions of anti-TNF therapy (adalimumab and inﬂ  iximab) in 
established RA was published recently (Bongartz et al 2006). 
The study found a signiﬁ  cantly increased risk for serious 
infections in patients treated with MTX- IFX (OR: 2; 95% CI 
1.3–3.2), but no difference between the low and high dosage 
of anti-TNF agents. Malignancies were found in 29 out of 
3493 patients receiving anti-TNF therapy compared with only 
3 patients in the group treated with non-biological DMARDs. 
The pooled OR for malignancy in the IFX group was of 3.3; 
(95% CI 1.2–9.1) compared with the control group. However 
it is important to note that 92% of the tumors reported in this 
meta-analysis occurred in patients treated with high doses 
unaccepted by the FDA (Callegari et al 2006). Even though 
anti-TNF agents have potentially serious side effects, it is 
important to remember that this new class of medication 
appears to diminish the cardiovascular morbidity and overall 
mortality in RA patients (Michaud and Wolfe 2005). Thus the 
effect of anti-TNF agents on survival is complex and should 
be assessed in long-term follow up studies.
Cost-effectiveness
We found no published cost-effectiveness analyses spe-
ciﬁ  cally for IFX in early RA. Cost-effectiveness analyses in 
advanced/chronic RA have shown a potential beneﬁ  t in favor 
of MTX-IFX in RA patients resistant to MTX (Kobelt et al 
2003, 2004; Barbieri et al 2005). However some limitations 
of these studies need to be discussed: Firstly, the comparator 
groups were historical patients from the 1980s, a time when 
antirheumatic therapy was much less effective than that used 
today. Secondly, the deﬁ  nition of costs was very heteroge-
neous among the different studies (direct medical costs and 
indirect costs). Yet the potential beneﬁ  t of early aggressive 
treatment on long-term disability might be of great inﬂ  u-
ence on secondary or indirect costs. Cost-effective analyses 
comparing MTX-IFX with intensive DMARD therapy in Therapeutics and Clinical Risk Management 2007:3(5) 909
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early RA, including both the direct and the indirect costs, are 
thus still needed.
Discussion
We identiﬁ  ed 6 clinical trials comparing the combination 
of MTX-IFX and MTX-placebo in early RA. These studies 
examined the effects of treatments on radiographic joint 
damage, composite disease activity measures and functional 
disability scores. Three studies also examined safety and no 
study analyzed speciﬁ  cally the cost-effectiveness of this new 
therapy in early RA. The results of these studies are in favor 
of IFX-MTX combination in terms of radiographic damage 
prevention and functional disability progression. The effect 
on disease activity, although signiﬁ  cant in some studies, is 
less striking. One smaller study showed a beneﬁ  cial effect 
on functional disability that persisted after the interruption of 
IFX therapy (Quinn et al 2005). If this result was conﬁ  rmed 
in larger studies, the cost-effectiveness of IFX would be 
indisputably increased in early RA. Higher dosages of IFX 
used in some studies were in general not associated with a 
statistically signiﬁ  cant improvement in clinical and radio-
logical outcomes (St Clair et al 2004). Furthermore, most of 
the malignancies reported were in that group. Thus starting 
with higher dosages of IFX seems to offer no advantage in 
early RA and potentially increases the risk associated with 
this therapy.
The positive results of MTX-IFX need to be put into per-
spective. Indeed, only the BEST study compared MTX-IFX 
with another combination of traditional DMARDs and found 
no statistically signiﬁ  cant difference in favor of MTX-IFX 
(Goekoop-Ruiterman et al 2005). Forty per cent of patients in 
the conservative sequential monotherapy group and step-up 
therapy group also obtained efﬁ  cient control of the disease 
(Goekoop-Ruiterman et al 2005). A recent meta-analysis 
examined the consequences of timing of IFX initiation on 
therapeutic effect sizes and concluded that the beneﬁ  t of 
biological agents are signiﬁ  cantly larger in RA patients with 
longer disease durations and in patients with previous MTX 
failure (M Lopez-Olivo 2006). This emphasizes the fact that 
MTX probably remains the anchor drug for the treatment of 
early RA, as recommended by several therapeutic guidelines 
(Combe et al 2006).
Some points of this review need consideration. Firstly, only 
2 large studies of IFX in early RA are published (ASPIRE and 
BEST) and much of the available data are based on one single 
trial (ASPIRE). Secondly, most of the patients included in 
Table 1 Randomized trials of inﬂ  iximab in early rheumatoid arthritis
    At study    Radiographic joint damage  Secondary outcomes
    inclusion    progression in 1 year
First author  N  Disease  IFX dosage  vdH-S score   vdH-S score
    duration    (IFX group)   (MTX group)
       (SD)  (SD)
St Clair et al 2004  1049  3 years  IFX 3 mg/kg  0.4 (5.8)  3.7 (9.6)  ACR response; DAS 28;
(ASPIRE trial)      IFX 6 mg/Kg  0.5 (5.6)  3.7 (9.6)  HAQ; adverse effects
Goekoop-Ruiterman et al 2005  508  3 years  IFX 3–6 mg/kg  –1.4 (4)  7.1 (–15.4)  HAQ score; adverse
(3 years BEST trial)            effects
Breedveld et al 2004  66  3 years  IFX 3 mg/kg  0.4 (–4.5)  9.1 (7.7)  vdH-Sharp score at 2
(ATTRACT sub-analysis)            years follow up
Taylor et al 2004  24  3 years  IFX 5 mg/Kg  3.3 (3.6)  12.2 (10.10)  US with power Doppler; 
            CRP; Swollen joint count
Quinn et al 2005  20  1 year        MRI scores at 1 year; 
            ACR response; DAS 28; 
            CRP; HAQ study
Smolen et al 2006  1004  3 years  IFX 3–6 mg/kg  a-  a- Employability;  ACR
(ASPIRE trial)            response; DAS 28;
Smolen et al 2006  1004  3 years  IFX 3–6 mg/kg  a-  a-  Correlation of CRP, ESR, 
(ASPIRE trial)            and disease activity with
           RX  progression
Taylor et al 2006  24  3 years  IFX 5 mg/Kg  a-  a- Synovial  thickness/color
            Doppler area/2 year
           therapy
aDuplicate data.
Abbreviations: ACR response, American College of Rheumatology response criteria; CRP, C-reactive protein; DAS, disease activity score; ESR, erythrocyte sedimentation 
rate; HAQ, Stanford Health Assessment Questionnaire; IFX, inﬂ  iximab; MRI, magnetic resonance imaging; MTX, methotrexate.Therapeutics and Clinical Risk Management 2007:3(5) 910
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these studies had moderate to severe disease activity, which 
limits the generalizability to all early RA patients. Thirdly, 
long-term results focusing on the beneﬁ  t and safety of IFX in 
early RA are scarce. Fourthly, data on cost-effectiveness of 
IFX in early RA are missing, which is a major concern con-
sidering the cost of this medication and current limitations in 
health care resources. Further data on the beneﬁ  t of early and 
potentially limited anti-TNF therapy on long-term disability 
are needed. Recent research reported in an abstract examined 
the long-term frequency of sustained good clinical responses 
and remissions in the BEST study between a group initially 
treated with methotrexate and prednisone and a group initially 
treated with methotrexate and IFX. Patients treated with IFX 
and methotrexate were signiﬁ  cantly more often in these low 
disease states 3 years after enrolment, despite by then receiving 
similar anti-rheumatic treatment (van der Kooij 2006).
Lastly, even though anti-TNF agents have potentially 
serious side effects, it is important to remember that this new 
class of medication appears to diminish the cardiovascular 
morbidity and overall mortality in RA patients (Michaud 
and Wolfe 2005). Thus the effect of anti-TNF agents on 
survival is complex and should be assessed in long-term 
follow up studies.
Conclusion
In early RA, IFX in combination with MTX is more effective 
than MTX alone in preventing joint damage, improving func-
tional disability, and reducing disease activity. Nonetheless, 
many patients with early RA probably do not require IFX to 
achieve a satisfying clinical response (Boers et al 1997; Boers 
1999). There is no evidence for the superiority of MTX-IFX 
over MTX in combination with traditional DMARDs. In our 
opinion, the prescription of IFX should be limited to early 
RA patients with clinical and biological signs of aggressive 
disease, such as an insufﬁ  cient response to MTX alone or 
the presence of rapidly progressing erosions. Nonetheless, 
early, short-term treatment with anti-TNF might be a cost-
effective option if the biologic treatment can be interrupted, 
and needs further evaluation.
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